Alethia Biotherapeutics: Yves Cornellier

Insight from Yves Cornellier, President and CEO of Alethia Biotherapeutics.

Founded in 2002 through an investment from Génome Québec to develop and apply functional genomic technology, Alethia Biotherapeutics has been specializing in therapeutic monoclonal antibodies since 2005. It is currently moving from basic research to drug development. (Video)

http://www.youtube.com/watch?v=S5TJet3oNXw